Advanced Enzyme Q1 Review - Strong Numbers With Addition Of SciTech Specialities: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Advanced Enzyme Technologies Ltd.'s Q1 FY22 revenues grew 24% YoY to Rs 137 crore on the back of 55.7% YoY growth in industrial processing segment to Rs 20.4 crore.
Animal healthcare witnessed growth of 32.1% YoY to Rs 14 crore whereas human healthcare segment grew by a mere 2.8% YoY to Rs 89.2 crore.
Ebitda margins contracted 101 basis points YoY to 45.8% mainly due to higher other expenditure.
Subsequently, Ebitda grew 21.3% YoY to Rs 62.8 crore while profit after tax grew 11.1% YoY to Rs 38 crore.
Delta vis-a-vis Ebitda was mainly due to lower other income.
Strong margins and healthy return ratios reflect the pricing power and balance sheet strength of Advanced Enzyme.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.